HONG KONG – Vietnam is emerging as a favorable market for multinational drugmakers, thanks to new trade agreements that provide more protection to patent holders and policies that welcome drug imports. Some companies have already made their moves in the populated Southeast Asian country.

HONG KONG – The Singapore government will be launching a pilot program that could help biotech and med-tech companies thrive in both the country and Asia. The two-year pilot, Tech@SG, set up by the Economic Development Board (EDB) and Enterprise Singapore, aims to provide companies access to business networks and talent.

HONG KONG – Chengdu-based Hinova Pharmaceuticals Inc., of China's Sichuan province, closed a series B financing that added $40 million to the company's pocket. 

TAIPEI, Taiwan – The three-day 2019 BIO Asia-Taiwan Conference and Exhibition opened on July 24 to discuss how biotechnology could be the next growth engine for Asia. While figures are suggesting Asia is rising as a biotech powerhouse, the region needs to think beyond just capital, talent and patient pools, speakers said.

TAIPEI, Taiwan – Western pharma players might not be addressing diseases that are specific to or predominant in Asia, speakers said on the second day of the recent BIO Asia-Taiwan conference, making regional collaboration important for developing therapeutics targeting unmet needs at home.

Taipei, TAIWAN – Asian capital continues to play a key role in funding biotech development regionally and globally through private investments, M&A deals or IPOs. And 2018 was a particularly exciting one for cross-border investments and health care IPOs, said speakers at the BIO Asia conference. The total deal value of global biopharma IPOs and M&A deals hit a record $49 billion in 2018.

TAIPEI, Taiwan – Budding Taiwanese startup Elixiron Immunotherapeutics Inc. closed a $10.5 million series A1 financing to further expand its technology platform and drive its drug candidates toward clinical development.

TAIPEI, Taiwan – Asian capital continues to play a key role in funding biotech development regionally and globally through private investments, M&A deals or IPOs. And 2018 was a particularly exciting one for cross-border investments and health care IPOs, said speakers at the BIO Asia conference. The total deal value of global biopharma IPOs and M&A deals hit a record $49 billion in 2018.

TAIPEI, Taiwan – Western pharma players might not be addressing diseases that are specific to or predominant in Asia, speakers said on the second day of the BIO Asia-Taiwan conference, making regional collaboration important for developing therapeutics targeting unmet needs at home.